Related Experiment Video
Updated: Apr 17, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Sclerostin and CKD-MBD
1Genzyme, Boston, MA, USA, scschiavi@gmail.com.
Abstract:
Declining kidney function is associated with sequential systemic changes in mineral homeostasis leading to pathologic alterations in the cardiovascular system and the skeleton. One of the earliest changes in response to renal injury is the increased osteocyte production of secreted factors including the anti-anabolic protein, sclerostin. Elevated sclerostin is associated with reduced Wnt/β-catenin signaling in bone and decreased osteoblast differentiation/activity. Agents that directly or indirectly inhibit β-catenin signaling have differential skeletal effects suggesting additional mechanisms contribute to the diversity of renal osteodystrophies. Similarly, Wnt/β-catenin activation in smooth muscle cells contributes to cardiovascular calcification yet emerging data suggests that this pathway may also be protective when elevated in neighboring tissues. The ongoing epidemiology studies examining the relationship between circulating sclerostin and cardiovascular disease, particularly those that investigate stage specific and/or patient sub-populations, will be useful in understanding the overall contributions of this pathway, its antagonist sclerostin, and the progression of CKD-MBD.
Insights
Declining kidney function alters mineral balance, affecting bones and the cardiovascular system. Elevated sclerostin, a protein linked to kidney disease, impacts bone health and may influence cardiovascular calcification.
Area of Science:
- Nephrology
- Endocrinology
- Bone Biology
Background:
- Chronic kidney disease (CKD) disrupts mineral homeostasis, leading to skeletal and cardiovascular complications.
- Osteocyte-derived sclerostin increases with renal injury, inhibiting bone formation via Wnt/β-catenin signaling.
- The role of Wnt/β-catenin signaling in CKD-mineral and bone disorder (CKD-MBD) is complex, with potential dual effects on bone and vasculature.
Purpose of the Study:
- To explore the role of sclerostin and Wnt/β-catenin signaling in the systemic changes associated with declining kidney function.
- To understand the differential skeletal effects of agents targeting β-catenin signaling in the context of CKD.
- To investigate the relationship between circulating sclerostin levels and cardiovascular disease progression in CKD patients.
Main Methods:
- Review of current literature on sclerostin, Wnt/β-catenin signaling, and CKD-MBD.
- Analysis of existing epidemiological data on sclerostin and cardiovascular outcomes in CKD.
- Discussion of the molecular mechanisms linking renal function, bone metabolism, and vascular health.
Main Results:
- Elevated sclerostin is an early indicator of renal injury, correlating with reduced bone formation.
- Wnt/β-catenin signaling inhibition by sclerostin contributes to diverse forms of renal osteodystrophy.
- Emerging data suggests Wnt/β-catenin signaling may have protective roles in cardiovascular health despite its role in calcification.
Conclusions:
- Sclerostin and Wnt/β-catenin signaling are critical mediators in CKD-MBD, influencing both skeletal and cardiovascular health.
- Further epidemiological studies are needed to elucidate the precise role of sclerostin in CKD progression and cardiovascular disease.
- Understanding these pathways is crucial for developing targeted therapies for CKD complications.
Related Concept Videos
Cytoskeletal Linker Proteins - Plakins
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Osteoclasts in Bone Remodeling
Skeleton and Calcium Homeostasis
Chronic Kidney Disease III: Interprofessional Care

